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Following publication of the original article in Clinical 
and Translational Medicine [1], it was brought to our 
attention that there is an error in the section “Safety mar-
gin considerations”.
The second sentence of the first paragraph of the sec-
tion “Safety margin considerations” currently reads: 
“For first-in-human studies applying a range of escalat-
ing doses, the FDA suggests a default safety factor of ten 
between the exposure for the starting dose and that of 
the Human Equivalent Dose, which should be individual-
ized [27]”.
This text should read: For first-in-human studies apply-
ing a range of escalating doses, the FDA suggests a default 
safety factor of ten between the NOAEL in GLP toxicol-
ogy studies in animals and the starting dose expressed 
as Human Equivalent Dose of the first-in-human study. 
The safety margin should be individualized by compound 
[27].
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